Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill.
Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill.
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658. doi: 10.1001/jamainternmed.2018.4637.
Colorectal cancer screening (CRC) is recommended by all major US medical organizations but remains underused.
To identify interventions associated with increasing CRC screening rates and their effect sizes.
PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and ClinicalTrials.gov were searched from January 1, 1996, to August 31, 2017. Key search terms included colorectal cancer and screening.
Randomized clinical trials of US-based interventions in clinical settings designed to improve CRC screening test completion in average-risk adults.
At least 2 investigators independently extracted data and appraised each study's risk of bias. Where sufficient data were available, random-effects meta-analysis was used to obtain either a pooled risk ratio (RR) or risk difference (RD) for screening completion for each type of intervention.
The main outcome was completion of CRC screening. Examination included interventions to increase completion of (1) initial CRC screening by any recommended modality, (2) colonoscopy after an abnormal initial screening test result, and (3) continued rounds of annual fecal blood tests (FBTs).
The main review included 73 randomized clinical trials comprising 366 766 patients at low or medium risk of bias. Interventions that were associated with increased CRC screening completion rates compared with usual care included FBT outreach (RR, 2.26; 95% CI, 1.81-2.81; RD, 22%; 95% CI, 17%-27%), patient navigation (RR, 2.01; 95% CI, 1.64-2.46; RD, 18%; 95% CI, 13%-23%), patient education (RR, 1.20; 95% CI, 1.06-1.36; RD, 4%; 95% CI, 1%-6%), patient reminders (RR, 1.20; 95% CI, 1.02-1.41; RD, 3%; 95% CI, 0%-5%), clinician interventions of academic detailing (RD, 10%; 95% CI, 3%-17%), and clinician reminders (RD, 13%; 95% CI, 8%-19%). Combinations of interventions (clinician interventions or navigation added to FBT outreach) were associated with greater increases than single components (RR, 1.18; 95% CI, 1.09-1.29; RD, 7%; 95% CI, 3%-11%). Repeated mailed FBTs with navigation were associated with increased annual FBT completion (RR, 2.09; 95% CI, 1.91-2.29; RD, 39%; 95% CI, 29%-49%). Patient navigation was not associated with colonoscopy completion after an initial abnormal screening test result (RR, 1.21; 95% CI, 0.92-1.60; RD, 14%; 95% CI, 0%-29%).
Fecal blood test outreach and patient navigation, particularly in the context of multicomponent interventions, were associated with increased CRC screening rates in US trials. Fecal blood test outreach should be incorporated into population-based screening programs. More research is needed on interventions to increase adherence to continued FBTs, follow-up of abnormal initial screening test results, and cost-effectiveness and other implementation barriers for more intensive interventions, such as navigation.
所有美国主要医学组织都推荐进行结直肠癌筛查(CRC),但使用率仍然较低。
确定与提高 CRC 筛查率相关的干预措施及其效果大小。
从 1996 年 1 月 1 日至 2017 年 8 月 31 日,在 PubMed、 Cumulative Index to Nursing and Allied Health Literature、 Cochrane Library 和 ClinicalTrials.gov 中进行了检索。主要搜索词包括结直肠癌和筛查。
在临床环境中进行的基于美国的干预措施的随机临床试验,旨在提高平均风险成年人的 CRC 筛查测试完成率。
至少有 2 名调查员独立提取数据,并对每项研究的偏倚风险进行评估。在有足够数据的情况下,使用随机效应荟萃分析获得每种干预措施完成 CRC 筛查的汇总风险比(RR)或风险差(RD)。
主要结果是 CRC 筛查的完成情况。检查包括增加(1)任何推荐方式的初始 CRC 筛查,(2)异常初始筛查测试结果后的结肠镜检查,和(3)年度粪便潜血检测(FBT)的连续轮次的干预措施。
主要综述包括 73 项随机临床试验,涉及低或中偏倚风险的 366766 名患者。与常规护理相比,与增加 CRC 筛查完成率相关的干预措施包括 FBT 外展(RR,2.26;95%CI,1.81-2.81;RD,22%;95%CI,17%-27%)、患者导航(RR,2.01;95%CI,1.64-2.46;RD,18%;95%CI,13%-23%)、患者教育(RR,1.20;95%CI,1.06-1.36;RD,4%;95%CI,1%-6%)、患者提醒(RR,1.20;95%CI,1.02-1.41;RD,3%;95%CI,0%-5%)、临床医生的学术细节干预(RD,10%;95%CI,3%-17%)和临床医生提醒(RD,13%;95%CI,8%-19%)。干预措施的组合(FBT 外展加临床医生干预或导航)比单一成分更能增加增加(RR,1.18;95%CI,1.09-1.29;RD,7%;95%CI,3%-11%)。有导航的重复邮寄 FBT 与增加年度 FBT 完成率相关(RR,2.09;95%CI,1.91-2.29;RD,39%;95%CI,29%-49%)。患者导航与初始异常筛查测试结果后的结肠镜检查完成率无关(RR,1.21;95%CI,0.92-1.60;RD,14%;95%CI,0%-29%)。
在美国的试验中,粪便潜血检测外展和患者导航与增加 CRC 筛查率相关,特别是在多组分干预的情况下。粪便潜血检测外展应纳入基于人群的筛查计划。需要更多的研究来干预措施,以提高对继续进行 FBT、对异常初始筛查测试结果的随访,以及对更密集干预措施(如导航)的成本效益和其他实施障碍的依从性。